Skip to main content

FDA Approvals

Zejula a New Maintenance Treatment Option for Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Breast Cancer, FDA Approvals, Oncology

Kisqali, a New CDK4/CDK6 Inhibitor, Approved as First-Line Therapy for HR-Positive, HER2-Negative Advanced Breast Cancer

FDA Approvals, Payers' Guide

FDA Approvals of Brand-Name Prescription Drugs in 2016

FDA Approvals, Payers' Guide

Welcome to the Eighth Annual Payers’ Guide to New FDA Approvals

Payers' Guide, FDA Approvals

Darzalex (Daratumumab) Approved as Part of a 3-Drug Regimen for Patients with Multiple Myeloma

Lisa A. Raedler, PhD, RPh

Payers' Guide, FDA Approvals

Defitelio (Defibrotide Sodium): First Drug Approved for Patients with Hepatic Veno-Occlusive Disease

Payers' Guide, FDA Approvals

Gazyva (Obinutuzumab) Approved for Patients with Rituximab-Refractory Follicular Lymphoma

Payers' Guide, FDA Approvals

Imbruvica (Ibrutinib) Now FDA Approved as First-Line Treatment for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Lisa A. Raedler, PhD, RPh

Payers' Guide, FDA Approvals

Lartruvo (Olaratumab) a Novel First-Line Treatment Approved for Patients with Advanced Soft-Tissue Sarcoma

Payers' Guide, FDA Approvals

Revlimid (Lenalidomide) Receives New Indication for Multiple Myeloma as Maintenance Therapy After Transplantation

Lisa A. Raedler, PhD, RPh

Page 32 of 53
Results 311 - 320 of 525